HOOKIPA Pharma Inc. – NASDAQ:HOOK
HOOKIPA Pharma stock price today
$0.816
-1.12
-57.96%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
HOOKIPA Pharma stock price monthly change
-68.96%
month
HOOKIPA Pharma stock price quarterly change
-68.96%
quarter
HOOKIPA Pharma stock price yearly change
+137.16%
year
HOOKIPA Pharma key metrics
Market Cap | 19.11M |
Enterprise value | N/A |
P/E | -0.74 |
EV/Sales | -4.65 |
EV/EBITDA | 1.09 |
Price/Sales | 2.78 |
Price/Book | 0.38 |
PEG ratio | 0.08 |
EPS | -0.53 |
Revenue | 53.55M |
EBITDA | -43.55M |
Income | -47.51M |
Revenue Q/Q | 1052.36% |
Revenue Y/Y | 235.11% |
Profit margin | -455.58% |
Oper. margin | -457.85% |
Gross margin | 0% |
EBIT margin | -457.85% |
EBITDA margin | -81.34% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHOOKIPA Pharma stock price history
HOOKIPA Pharma stock forecast
HOOKIPA Pharma financial statements
| Jun 2023 | 2.67M | -18.01M | -672.49% |
|---|---|---|---|
| Sep 2023 | 6.86M | -19.06M | -277.65% |
| Dec 2023 | 7.40M | -24.81M | -335.06% |
| Mar 2024 | 36.59M | 14.38M | 39.3% |
| Mar 2024 | 36.59M | 14.38M | 39.3% |
|---|---|---|---|
| Sep 2025 | 2M | -18.80M | -940.03% |
| Oct 2025 | 2M | -25.19M | -1259.76% |
| Dec 2025 | 2M | -25.19M | -1259.76% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 191110000 | 78.78M | 41.22% |
|---|---|---|---|
| Sep 2023 | 164010000 | 68.95M | 42.05% |
| Dec 2023 | 161337000 | 71.48M | 44.3% |
| Mar 2024 | 145871000 | 41.34M | 28.35% |
| Jun 2023 | -19.33M | -445K | 45.81M |
|---|---|---|---|
| Sep 2023 | -24.11M | -3.01M | -659K |
| Dec 2023 | -11.22M | -422K | 21.24M |
| Mar 2024 | -24.15M | -116K | -135K |
HOOKIPA Pharma alternative data
| Aug 2023 | 156 |
|---|---|
| Sep 2023 | 156 |
| Oct 2023 | 156 |
| Nov 2023 | 156 |
| Dec 2023 | 156 |
| Jan 2024 | 156 |
| Feb 2024 | 156 |
| Mar 2024 | 151 |
| Apr 2024 | 151 |
| May 2024 | 151 |
| Jun 2024 | 151 |
| Jul 2024 | 151 |
HOOKIPA Pharma other data
12.85%
-20.04%
of HOOK is owned by hedge funds
23
-27
8.41M
-15.33M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 12000 | 0 |
| Jul 2023 | 20000 | 0 |
| Aug 2023 | 15000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | KANDERA REINHARD director, officer.. | Common Stock | 7,000 | $0.73 | $5,075 | ||
Purchase | KANDERA REINHARD director, officer.. | Common Stock | 8,000 | $0.71 | $5,712 | ||
Purchase | ALDAG JORN director, officer: Chief Execut.. | Common Stock | 5,000 | $0.83 | $4,140 | ||
Purchase | ALDAG JORN director, officer: Chief Execut.. | Common Stock | 5,000 | $0.81 | $4,050 | ||
Purchase | ALDAG JORN director, officer: Chief Execut.. | Common Stock | 5,000 | $0.89 | $4,450 | ||
Purchase | ALDAG JORN director, officer: Chief Execut.. | Common Stock | 5,000 | $0.89 | $4,455 | ||
Purchase | KANDERA REINHARD director, officer.. | Common Stock | 12,000 | $0.88 | $10,560 | ||
Option | MATUSHANSKY IGOR officer: Chief Me.. | Stock Option (Right to Buy) | 22,853 | $0.1 | $2,285 | ||
Sale | MATUSHANSKY IGOR officer: Chief Me.. | Common Stock | 14,949 | $2.49 | $37,223 | ||
Option | MATUSHANSKY IGOR officer: Chief Me.. | Common Stock | 22,853 | $0.1 | $2,285 |
| Quarter | Transcript |
|---|---|
| Q4 2022 15 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q4 2021 24 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q4 2020 18 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Q4 2019 19 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Joern Aldag (1959) Chief Executive Officer & Director | $793,040 |
| Dr. Igor Matushansky M.D., Ph.D. (1973) Chief Medical Officer and Global Head of R&D | $602,930 |
| Dr. Reinhard Kandera (1969) Chief Financial Officer & Director | $562,080 |
-
What's the price of HOOKIPA Pharma stock today?
One share of HOOKIPA Pharma stock can currently be purchased for approximately $0.82.
-
When is HOOKIPA Pharma's next earnings date?
Unfortunately, HOOKIPA Pharma's (HOOK) next earnings date is currently unknown.
-
Does HOOKIPA Pharma pay dividends?
No, HOOKIPA Pharma does not pay dividends.
-
How much money does HOOKIPA Pharma make?
HOOKIPA Pharma has a market capitalization of 19.11M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 41.27% to 20.13M US dollars.
-
What is HOOKIPA Pharma's stock symbol?
HOOKIPA Pharma Inc. is traded on the NASDAQ under the ticker symbol "HOOK".
-
What is HOOKIPA Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of HOOKIPA Pharma?
Shares of HOOKIPA Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are HOOKIPA Pharma's key executives?
HOOKIPA Pharma's management team includes the following people:
- Mr. Joern Aldag Chief Executive Officer & Director(age: 66, pay: $793,040)
- Dr. Igor Matushansky M.D., Ph.D. Chief Medical Officer and Global Head of R&D(age: 52, pay: $602,930)
- Dr. Reinhard Kandera Chief Financial Officer & Director(age: 56, pay: $562,080)
-
How many employees does HOOKIPA Pharma have?
As Jul 2024, HOOKIPA Pharma employs 151 workers.
-
When HOOKIPA Pharma went public?
HOOKIPA Pharma Inc. is publicly traded company for more then 6 years since IPO on 18 Apr 2019.
-
What is HOOKIPA Pharma's official website?
The official website for HOOKIPA Pharma is hookipapharma.com.
-
Where are HOOKIPA Pharma's headquarters?
HOOKIPA Pharma is headquartered at 350 Fifth Avenue, New York, NY.
-
How can i contact HOOKIPA Pharma?
HOOKIPA Pharma's mailing address is 350 Fifth Avenue, New York, NY and company can be reached via phone at +43 1 8906360.
HOOKIPA Pharma company profile:
HOOKIPA Pharma Inc.
hookipapharma.comExchange:
NASDAQ
Full time employees:
151
Industry:
Biotechnology
Sector:
Healthcare
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
350 Fifth Avenue
New York, NY 10118
New York, NY 10118
CIK: 0001760542
ISIN: US43906K1007
CUSIP: 43906K100
